AoYang Health (002172.SZ) announced first-half results, with net profit of 24.1647 million yuan to mother, a year-on-year decrease of 23.42%

According to the Zhitong Finance App, Aoyang Health (002172.SZ) released its 2026 semi-annual report. During the reporting period, the company achieved revenue of 823 million yuan, a year-on-year decrease of 8.89%. Net profit attributable to shareholders of listed companies was 24.1647 million yuan, a year-on-year decrease of 23.42%. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 19.2463 million yuan, a year-on-year decrease of 35.14%. Basic earnings per share were $0.03.

During the reporting period, Australian and Western pharmaceutical logistics continued to improve its market layout. It has formed an integrated sales market network with southern Jiangsu as the core, covering the entire region of Jiangsu Province, and covering East China regions such as Shanghai, Zhejiang, and Anhui. The company continues to increase investment in logistics system intelligence and informatization upgrades, and further optimizes logistics equipment and operation processes. It is at the forefront of the East China industry in terms of design concept, operation efficiency, sorting speed, and distribution categories. The quality of logistics services and operational efficiency continue to improve, forming a strong core competitiveness in the East China pharmaceutical distribution market.